[{"orgOrder":0,"company":"Sanofi","sponsor":"CORONA remedies","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Thiocolchicoside","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sanofi","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ CORONA remedies","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ CORONA remedies"}]

Find Clinical Drug Pipeline Developments & Deals for Thiocolchicoside

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Thiocolchicoside

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Approved

                          Sponsor : CORONA remedies

                          Deal Size : $28.5 million

                          Deal Type : Acquisition

                          Details : Through the acquisition, Corona Remedies gains right for the leading muscle relaxant brand Myoril (thiocolchicoside) and its extensions such as Myoril Plus (ketoprofen and thiocolchicoside) to treat muscular pain.

                          Brand Name : Myoril

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 28, 2023

                          Lead Product(s) : Thiocolchicoside

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : CORONA remedies

                          Deal Size : $28.5 million

                          Deal Type : Acquisition

                          Sanofi Company Banner